| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03858049 Details | 2024-03-12 Interventional | 4 | 172 | Dydrogesterone Infertility | The trend in LPS treatment tends to increase the dosage of progesterone in FET-HRT, this study
was designed 5 years ago. - | |||
| NCT03646188 Details | 2024-03-12 Interventional | 1 | 13 | Doxorubicin Liposomal doxor… Carcinoma Carcinoma, Basa… Basal Cell Carc… | Application of arrays was inconsistent. - | |||
| NCT03151057 Details | 2024-03-12 Interventional | 1 | 16 | Idelalisib Leukemia, Lymph… Lymphoma Lymphoma, Mantl… Lymphoma, Non-H… B Cell Chronic … B Cells-Tumors Follicular Lymp… Large B-Cell Di… Mantle Cell Lym… | Safety endpointreached - | |||
| NCT02762266 Details | 2024-03-12 Interventional | 3 | 13 | Ethiodized Oil Carcinoma Carcinoma, Hepa… Recurrence Child-Pugh Clas… Child-Pugh Clas… Recurrent Hepat… | Business decision - funding This study did not enroll the planned number of participants and did not meet the protocol-prespecified threshold for statistical significance. | |||
| NCT01953926 2013-002872-42 Details | 2024-03-12 Interventional | 2 | 582 | Fulvestrant Neratinib Paclitaxel Trastuzumab Neoplasms Solid Tumors Ha… | The study was terminated to align with the sponsor's current development plans for neratinib.
The decision was not based on any new efficacy or safety data for neratinib. - | |||
| NCT01886794 Details | 2024-03-12 Interventional | 4 | 10 | Estrogens Pelvic Floor Di… Pelvic Organ Pr… Prolapse | Collaborator moved and not able to recreate full study team - | |||
| NCT01764451 Details | 2024-03-12 Interventional | 1 | 12 | Simvastatin Congenital Abno… Hemangioma Hemangioma, Cav… Hemangioma, Cav… Cavernous Angio… Cerebral Cavern… Cerebral Cavern… | Research was completed before January 18, 2017, & does not meet the Applicable Clinical Trial
requirement to register & report results per the guidance provided in "Clinical Trials
Registration & Results Information Submission" dated 09/21/2016. - | |||
| NCT05946811 Details | 2024-03-08 Interventional | 3 | 0 | Macitentan Embolism Pulmonary Embol… | Study was cancelled by funding agency before starting enrollment. - | |||
| NCT05720988 Details | 2024-03-08 Interventional | 1 | 0 | Azacitidine Leukemia Leukemia, Myelo… Leukemia, Myelo… Neoplasm, Resid… Acute Myeloid L… | trial was not opened - | |||
| NCT05689359 Details | 2024-03-08 Interventional | 2 | 0 | Hydroxychloroqu… Breast Neoplasm… Peripheral Nerv… Breast Cancer Chemotherapy-in… Early-stage Bre… Gynecologic Can… Peripheral Neur… | Per Principal Investigator, it is not feasible to move forward with this trial. - | |||
| NCT05473234 Details | 2024-03-08 Interventional | 3 | 307 | Amoxicillin Azithromycin Malnutrition Severe Acute Ma… | Study was halted due to low follow-up rates and issues with data collection - | |||
| NCT05361993 Details | 2024-03-08 Interventional | 4 | - | Aripiprazole Tic Disorders Tics | External factor: trial equipment problems - | |||
| NCT05056727 2021-001911-96 Details | 2024-03-08 Interventional | 3 | 716 | Irbesartan Lisinopril Valsartan Hyperkalemia Renal Insuffici… Renal Insuffici… | The study started enrollment in Sep 2021 and despite huge efforts the rate of patient
enrollment continued to be below target such that the completion of the study within a
reasonable timeframe was deemed very unlikely. - | |||
| NCT04905563 Details | 2024-03-08 Interventional | 4 | 30 | Acetaminophen Acetaminophen, … Hydrocodone Ibuprofen Fractures, Bone Humeral Fractur… Supracondylar H… | Clinical evidence supporting the hypothesis of this study has been published - | |||
| NCT04870112 2020-006041-18 Details | 2024-03-08 Interventional | 1 | 18 | Carboplatin Durvalumab Etoposide Carcinoma, Non-… Lung Neoplasms Small Cell Lung… Non-Small Cell … Small Cell Lung… | AstraZeneca has decided to stop further enrollment and the study was terminated when all
patients in Part 1 completed their last study visit. No safety issues or clinical concerns
however, have been identified for this study. Part 2 was not initiated - | |||
| NCT04478695 Details | 2024-03-08 Interventional | 1 | 1 | Pembrolizumab Leukemia Leukemia, Myelo… Leukemia, Myelo… Relapsed or Ref… | Amgen Decision This study was early terminated, leading to a small number of participants enrolled and analyzed. | |||
| NCT06085638 Details | 2024-03-07 Interventional | 1/2 | 0 | Azacitidine Venetoclax Leukemia Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Chronic Myelomo… | Zero participants accrued - | |||
| NCT05691478 NCT05683197 Details | 2024-03-07 Interventional | 2/3 | - | Cisplatin Doxorubicin Liposomal doxor… Methotrexate Osteosarcoma High Grade Oste… Localized Osteo… Metastatic Oste… Secondary Osteo… | Scheduled Interim Monitoring - | |||
| NCT05034562 Details | 2024-03-07 Interventional | 2 | 0 | Edetic Acid Gallium 68 PSMA… Carcinoma Prostatic Neopl… Metastatic Pros… Recurrent Prost… Stage IV Prosta… Stage IVA Prost… Stage IVB Prost… | Per PI no participants enrolled - | |||
| NCT04913675 Details | 2024-03-07 Interventional | 3 | 1065 | Sotrovimab COVID-19 Covid19 | The safety sub-study was discontinued early in the context of evolving variants with increased
fold changes in the in vitro half maximal inhibitory concentration (IC50) and uncertainty in
the clinical relevance of these changes The pre-specified daily imputation resulted in overly high inflation in the estimated progression rates for missing data. To reduce this bias and to account for progression history, weekly imputation was used for final conclusions. |